Wuhan HealthCare Biotechnology Co., Ltd. (SRN-CN-MF-000033113) is located in Optics Valley Precision Medicine Industry Park, and was founded on February 19, 2013. As a high-tech enterprise, the company integrates R&D, production, sales and testing services, with a strategic focus on precision medical diagnostic products for major diseases such as cancer and cardiovascular-cerebrovascular diseases.

Since its establishment, the company has been committed to developing more efficient diagnostic products with strong emphasis on independent R&D. It has built multidisciplinary R&D teams covering clinical medicine, molecular biology, microfluidics, mechanical automation and other fields. The company owns more than 10 invention patents and possesses proprietary core technology for the preparation of fluorescence in situ hybridization probes with fully independent intellectual property rights, which has reached an internationally advanced level.

Based on this patented technology, the new-generation probe hybridization incubation time is only 2 hours, reducing the total detection time of fluorescence in situ hybridization from 3 days to a few hours. The products feature higher sensitivity, specificity and excellent signal-to-noise ratio.

Meanwhile, the company has established a complete domestic and international marketing system. Its products have been introduced to more than 30 countries and regions overseas, earning a good market reputation and wide customer recognition, making it a leading brand in rapid fluorescence in situ hybridization probes worldwide.

Adhering to the tenet of “Fastness, Precision, and Beyond Expectation”, the company continues to make unremitting efforts to contribute to the development of global precision medicine.